Vivos Therapeutics, Inc. (VVOS)
| Market Cap | 11.51M |
| Revenue (ttm) | 17.44M |
| Net Income (ttm) | -21.17M |
| Shares Out | 13.49M |
| EPS (ttm) | -2.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,020 |
| Open | 0.854 |
| Previous Close | 0.863 |
| Day's Range | 0.854 - 0.854 |
| 52-Week Range | 0.808 - 7.950 |
| Beta | 6.90 |
| Analysts | Strong Buy |
| Price Target | 2.75 (+222.2%) |
| Earnings Date | Apr 15, 2026 |
About VVOS
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related t... [Read more]
Financial Performance
In 2025, Vivos Therapeutics's revenue was $17.44 million, an increase of 16.05% compared to the previous year's $15.03 million. Losses were -$21.17 million, 90.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for VVOS stock is "Strong Buy." The 12-month stock price target is $2.75, which is an increase of 222.20% from the latest price.
News
Vivos Therapeutics Earnings Call Transcript: Q4 2025
Revenue grew 16% in 2025, driven by SCN acquisition and a shift to a medical provider model, offsetting legacy declines. Gross margin held at 60%, but net loss widened due to integration costs. Expansion, insurance access, and SO team deployment are expected to drive growth in 2026.
Vivos Therapeutics Reports Full Year 2025 Financial Results
Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call t...
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatme...
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
LITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatme...
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare
Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
LITTLETON, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatm...
Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies
Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep relat...
Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds
LITTLETON, Colo., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep relat...
Vivos Therapeutics Transcript: Fireside Chat
A transformative year saw a strategic pivot to a vertically integrated model, driving a 76% revenue surge and high EBITDA margins. Rapid expansion, improved insurance coverage, and new affiliate partnerships position the company for national growth and industry consolidation.
Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
LITTLETON, Colo., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on sleep relat...
Vivos Therapeutics Earnings Call Transcript: Q3 2025
Q3 2025 saw revenue jump 76% year-over-year, driven by the SCN acquisition and new treatment centers, while net loss widened due to upfront costs. Management expects continued strong growth, improved margins, and cash flow break-even as new providers are onboarded and affiliations expand.
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference cal...
Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call
LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the del...
Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the developmen...
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the developmen...
Vivos Therapeutics Earnings Call Transcript: Q2 2025
Q2 2025 saw a strategic pivot with the SCN acquisition, driving sequential revenue growth and strong demand for new SO teams, despite a year-over-year revenue decline and higher operating losses from integration costs. Management expects cash flow positivity by Q4 2025 as expansion continues.
Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatmen...
Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...
New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children
LITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OS...
Vivos Therapeutics Earnings Call Transcript: Q1 2025
Q1 2025 saw a strategic pivot to acquiring sleep medical providers, with product sales up 8% but total revenue down due to lower service revenue. The SCN acquisition is expected to be immediately accretive, with positive cash flow forecast by year-end 2025.
Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call
LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development a...
Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada
By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to clos...
Vivos Therapeutics Earnings Call Transcript: Q4 2024
Revenue grew 9% to $15M in 2024, driven by a 26% increase in product sales and a strategic shift to alliances and acquisitions. Operating loss fell 35% as costs were cut, and new FDA clearances and international expansion set the stage for stronger growth in 2025.